Moderna’s RSV Vaccine Decision Postponed by FDA to Late May
FDA, Moderna, RSV vaccine, decision, delay, May
Revolutionizing Medicine: The Evolution and Future of Cell and Gene Therapy Manufacturing
Cell therapy manufacturing, gene therapy manufacturing, biomanufacturing, advanced therapies, CAR-T cell therapy, stem cell therapy, viral vectors, bioreactors, automation, scale-up, regulatory compliance, personalized medicine.
Shionogi Acquires Maze’s Pompe Disease Drug Following FTC’s Sanofi Deal Halt
Shionogi, Maze, Pompe disease, drug acquisition, FTC, Sanofi, $150 million
Revolutionary Gene Insertion Techniques Unveiled at #ASGCT24: A Glimpse into the Future of Genetic Engineering
Gene Insertion Techniques, #ASGCT24, Genetic Engineering, Scientists, Startups, Closed Doors
Sanofi Invests $500M in Novavax’s Covid Vaccine, Exploring Commercialization and Flu Combination
Sanofi, Novavax, Covid vaccine, commercialization, flu combination, $500M investment
MacroGenics Reviews Safety Protocols Following Three Patient Deaths in Prostate Cancer Drug Trial
MacroGenics, Phase 2 trial, prostate cancer, patient deaths, safety review, margetuximab, bispecific antibody
Novo Nordisk and Metaphore Pharmaceuticals Join Forces in a $600 Million Partnership to Pioneer Innovative Obesity Treatments
Novo Nordisk, Metaphore Pharmaceuticals, obesity drugs, next-generation treatments, $600 million deal, partnership, pharmaceutical collaboration, weight loss medications, metabolic disorders.
Takeda Pharmaceuticals Revises Profit Forecast Due to Vyvanse Patent Expiration, Plans $900M Restructuring by 2024
Takeda Pharmaceuticals, Vyvanse, patent expiration, profit outlook, restructuring, ADHD medication
Royalty Pharma Invests $525 Million in Sanofi-Licensed Multiple Sclerosis Therapy Royalties and Milestones
Royalty Pharma, Sanofi, multiple sclerosis therapy, royalties, milestones, investment, healthcare, pharmaceuticals, licensing
Revolutionary Gene Therapy Advancements: Early Trial Results from Leading Biotech Companies
ASGCT24, gene therapy, early trial results, Freeline, Rocket, Creyon, biotech companies, genetic diseases, hemophilia, liver diseases, Parkinson’s disease.